

Fig. 1A






Fig. 1B



4/23



**Fig.2B**





Fig. 3A



7/23







Fig. 4A





9/23





**Fig. 5B**




Fig. 6A

12/23




Fig. 7A




Fig. 7B










Fig. 7C












Fig. 9A




Fig. 9B






Fig.9C



**Figure 10. Determination of ApoC-III level in 14 haemorrhagic and 13 ischaemic stroke plasma samples compared to 30 negative controls using Daiichi tests (Cobas Mira plus automate)**



|           | P<br>(student test) | Sensitivity | Specificity |
|-----------|---------------------|-------------|-------------|
| I vs H    | 0.0342              | 92.3 %      | 71.42 %     |
| I vs Ctrl | 0.025               | 92.3 %      | 50 %        |
| H vs Ctrl | 0.4682              | -           | -           |

Fig. 11

